Introduction
============

It has become evident that self-reactive T cells with the potential to cause autoimmune disease comprise a part of the normal T-cell repertoire, but their activation is prevented by suppressor cells \[[@B1]-[@B3]\]. Although originally described in the 1970s \[[@B4]\], significant progress in characterizing suppressor T-cell subsets has been made only recently, where they have been renamed \'regulatory\' T cells.

A subset of thymus-derived CD4^+^ cells that constitutively expresses CD25, the α-chain of the IL-2 receptor, protect their host from spontaneous organ-specific autoimmune diseases. These CD4^+^ CD25^+^ cells have been called \'professional\' suppressor cells and have a contact-dependent mechanism of action, at least *in vitro*\[[@B5]\]. Other subsets of CD4^+^ and CD8^+^ cells, natural killer T cells, and cells displaying γδ TCRs also have downregulatory (suppressor) activity. In the periphery, suppressor T cells generated in response to environmental antigens protect their hosts from immune-mediated tissue injury by producing immunosuppressive cytokines.

The mechanisms responsible for the generation of suppressor T cells were poorly understood until recently. Our group has accumulated evidence that the multifunctional cytokine transforming growth factor-β (TGF-β) plays an essential role in the expansion of thymus-derived, professional, CD4^+^ CD25^+^ precursors that circulate in the blood. TGF-β also plays a key role in the generation of peripherally induced CD4^+^ and CD8^+^ cytokine-producing suppressor cell subsets.

This article will briefly review the evidence for contact-mediated and cytokine-producing suppressor cells, especially in humans, and the role of TGF-β in the generation of these cells. This knowledge can be used to generate suppressor T cells *ex vivo* in large numbers, and raises the possibility that the transfer of these cells back to the donor can serve as a therapy for autoimmune diseases such as systemic lupus erythematosus (SLE). This T-cell-based therapy could also be used to prevent graft rejection.

Thymus-dependent, \'professional\', contact-dependent, regulatory T cells
=========================================================================

The existence of thymus-derived suppressor cells was suggested by studies in mice where neonatal thymectomy on day 3 led to the development of a multiorgan autoimmune disease \[[@B6]\]. This disease is due to the loss of CD4^+^ CD25^+^ suppressor cells that do not appear until the first week after birth \[[@B7],[@B8]\]. Mature CD4^+^ CD25^+^ cells are found in the CD45RB^low^ activated/memory fraction mouse T cells. Because potentially aggressive, self-reactive T cells are found in the CD45RB^hi^ naive fraction of mouse T cells, the injection of CD45RB^hi^ cells from nonautoimmune, normal mice into immunodeficient mice results in generalized, multiorgan inflammatory disease. Similar to neonatal thymectomy, this disease is prevented by supplementing the injected cells with purified CD4^+^ CD25^+^ cells \[[@B9],[@B10]\]. Because these thymus-derived CD4^+^ CD25^+^ T cells appear to be crucial for the prevention of spontaneous autoimmune diseases, they have been called \'professional\' suppressor cells \[[@B5],[@B8]\].

In general, the properties of rodent and human CD4^+^ CD25^+^ T cells appear to be very similar. In humans, 6--18% of CD4^+^ T cells constitutively express CD25 \[[@B11]-[@B17]\]. Purified CD4^+^ CD25^+^ cells do not proliferate in response to cross-linking of their TCRs. They inhibit the activation of other T cells by a contact-dependent mechanism \[[@B5]-[@B17]\]. A large percentage constitutively express intracellular cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4 or CD152), the IL-2 receptor β-chain (CD122), transferrin receptors (CD71) and class II MHC markers \[[@B17]\].

Almost all the CD4^+^ CD25^+^ are in the \'activated\' state (CD45RB^low^ in the mouse, CD45RA^-^ RO^+^ in the human). This suggests they may be continuously stimulated by their internal environment. Although activation of CD4^+^ CD25^+^ cells is antigen specific, once these cells are activated they not only suppress T cells stimulated by the same antigen, but they also inhibit T cells stimulated by other antigens; so-called bystander effects \[[@B18]\]. Although CD4^+^ CD25^+^ cells are nonresponsive to cross-linking their TCRs, they do proliferate when costimulated with IL-2 or anti-CD28.

Cytokine production by CD4^+^ CD25^+^ cells is controversial. While some groups claim that these cells do not produce cytokines \[[@B8],[@B17]\], other groups have found that they can produce IL-10 \[[@B12],[@B13],[@B19]\], TGF-β \[[@B15],[@B19]\], IL-4 \[[@B12]\] and low amounts of interferon-γ \[[@B15]\]. All groups agree that these cells do not produce IL-2 and that they have a contact-dependent mechanism of action. Their suppressive activities are not abolished by neutralizing antibodies to IL-10, and all groups agree that suppression is not abolished by anti-TGF-β, but for one exception \[[@B19]\]. Nakamura *et al*. reported that immunosuppression by CD4^+^ CD25^+^ regulatory T cells is mediated by cell surface-bound TGF-β \[[@B19]\]. Many of these differences can possibly be explained by the heterogeneity of CD4^+^ CD25^+^ T cells. One group separated human CD4^+^ CD25^+^ cells into high- and low-intensity fractions by cell sorting, and they found that the suppressive effects were only displayed by the high-intensity fraction \[[@B17]\]. This subset did not produce cytokines.

Cytokine-dependent regulatory T cells
=====================================

CD8^+^ and CD4^+^ T cells that produce immunosuppressive cytokines have been described. Those that produce predominantly TGF-β and variable amounts of IL-10 and IL-4 have been called Th3-type cells, and they have been generated *in vivo* by immunization through an oral or other mucosal route \[[@B2],[@B20]\]. This route of antigen administration, however, does not only result in Th3 cells. Both Th2 cells and CD4^+^ CD25^+^ cells can also be generated by this procedure \[[@B20]-[@B22]\]. The conditions needed for the generation of Th3 cells are poorly understood.

Other workers have produced regulatory CD4^+^ cells by repeatedly stimulating with the antigen in the presence of IL-10 \[[@B23]-[@B26]\], or using immature antigen-presenting cells that lack potent costimulatory activity \[[@B27]\]. These regulatory CD4^+^ cells have been called Treg 1 (Tr1) cells and they produce significant quantities of IL-10. They do not proliferate in response to antigen and do not produce IL-2. Therefore, they are anergic.

Th3 and Tr1-like cells have been described in humans. One group has reported the appearance of Th3 cells in patients with multiple sclerosis following oral administration of myelin basic protein \[[@B28]\]. Human Tr1 cells suppressed an alloantigen-induced proliferative response \[[@B29]\]. Th3 or Tr1 cells mediate antigen-specific cellular hyporesponsiveness in patients with chronic helminth infections \[[@B30]\].

The fact that some regulatory T cells produce predominantly TGF-β and others IL-10 is not fortuitous. The combination of TGF-β and IL-10 is more immunosuppressive than either of the cytokines by themselves \[[@B31]\]. Significantly, shortly after antigen activation, T cells downregu-late their signal transducing type II receptor (TGF-βRII) and become refractory to the effects of TGF-β \[[@B32]\]. These cells then become mature effector cells. IL-10 appears as a feedback regulator later in the response and induces the re-expression of TGF-βRII. The synergistic inhibitory effects of TGF-β and IL-10 then terminate the response.

Whether Th3 cells and Tr1 cells come from similar precursors or comprise different subsets of regulatory T cells is not known. Many variables determine the differentiation pathway that a naive T cell will take following activation. These include the antigen concentration and route of administration, the cytokine milieu, and the pattern of costimulatory signals. Self-MHC-reactive T cells in humans can either provide B-cell helper function or suppress antibody production, depending on how they are activated. In each case, regulatory function depends on the cytokines produced \[[@B33]\]. In determining the T-cell response to myelin basic protein, another group found that TCR usage was similar whether the T cells became Th1 encephalitogenic cells or regulatory Th3 cells \[[@B34]\]. These studies suggest common precursors for T cells that take different differentiation pathways.

TGF-β induces CD4^+^ and CD8^+^ T cells to become suppressor cells
==================================================================

While TGF-β has well-known inhibitory effects on lymphocyte cytokine production and functional properties \[[@B35]\], our laboratory has accumulated data that these effects can be overcome by IL-2 and can be superceded by costimulatory activities. The net effect is that TGF-β induces IL-2-activated CD8^+^ and CD4^+^ T cells to develop potent suppressive activities. In parallel, other groups have observed that TGF-β inhibits the differentiation of T cells to Th1 or Th2 subsets \[[@B36],[@B37]\].

The initial observation that TGF-β is an IL-2-dependent differentiation factor for regulatory T cells was made in a study designed to determine the conditions required for human CD8^+^ T cells to become suppressors of antibody production. Using a model where we could induce T-cell-dependent antibody production without accessory cells, we found that CD4^+^ T cells, by themselves, lacked suppressor-inducing activity. The CD4^+^ cells produced IL-2 but, notwithstanding previous reports \[[@B38],[@B39]\], this cytokine could not induce suppressor cells by itself. We learned that the interaction of IL-2-activated natural killer cells with CD8^+^ cells leads to the production of active TGF-β, and that the presence of this cytokine was critical for CD8^+^ cells to suppress antibody production (Figure [1](#F1){ref-type="fig"}) \[[@B40],[@B41]\]. Moreover, the suppression was cytokine dependent and was abolished by a neutralizing anti-TGF-β monoclonal antibody (JD Gray and DA Horwitz, unpublished observation, 2000). Both IL-2 and TGF-β were thus critical for CD8^+^ cells to become Th3-like regulatory cells.

We have also induced CD4^+^ T cells to become Th3 cells. We used the superantigen, staphylococcal enterotoxin B, as the T-cell activating agent. Low-dose staphylococcal enterotoxin B can induce T-cell-dependent antibody production without additional accessory cells \[[@B42]\]. Briefly exposing CD4^+^ cells to TGF-β downregulated B-cell helper activity and induced certain CD4^+^ cells to develop suppressive activity that was neutralized by anti-TGF-β. Activating both CD4^+^ and CD8^+^ cells in the presence of TGF-β thus induced them to develop cytokine-dependent suppressive activity \[[@B43]\]. Other workers have also reported similar effects of TGF-β on CD8^+^ T cells \[[@B44]\]. One group found that IL-4 and TGF-β are involved in the differentiation of naive CD4^+^ cells to cytokine-producing Th3-type cells \[[@B45]\]. Another group reported that *in vitro* differentiation of Th3-type cells from Th0 precursors from TCR transgenic mice is enhanced by culture with TGF-β \[[@B20]\].

We next focused our attention on the induction of naive (CD45RA^+^RO^-^) CD4^+^ T cells to become suppressor cells. Using the alloantigens as the T-cell activating agent, we found that TGF-β induced naive CD4^+^ T cells to develop extremely potent suppressive activity. These CD4^+^ cells had the phenotype and functional characteristics of \'professional\' regulatory T cells. Using the generation cytotoxic T-cell activity and T-cell proliferation to assess suppressive activity, we learned that the suppressor cells were CD25^+^, and that a large percentage expressed CTLA-4. Their suppressive effects were contact dependent and were not neutralized by anti-TGF-β or IL-10. Adding less than 1% of these cells to T cells strongly inhibited the generation of cytotoxic T-lymphocyte activity by preventing the activation of CD8^+^ cells \[[@B14]\]. Other workers have also reported that CD4^+^ CD25^+^ cells have potent suppressive effects on CD8^+^ cells. Rodent CD4^+^ CD25^+^ regulatory cells cause CD8^+^ cells to enter cycle arrest \[[@B46]\].

The precursors of the human CD4^+^ CD25^+^ T cells induced by IL-2 and TGF-β appear to be the small number of CD25^+^ cells in the naive fraction. Although \<1% of these cells express CD25, depletion of these cells abrogated the generation of suppressive activity in some experiments \[[@B14]\]. The principal difference between the cytokine-induced CD4^+^ CD25^+^ cells and the murine and human positively selected CD4^+^ CD25^+^ cells that are predominantly found in the CD45RO^+^ \'memory\' fraction is their capacity for expansion. The positively selected cells are anergic while the CD4^+^ CD25^+^ cells generated from naive cells can be expanded in IL-2 and retain their suppressive activity \[[@B14]\].

Studies on the mechanism of action of TGF-β have revealed that this cytokine has potent costimulatory effects on IL-2-activated T cells. These effects include upregulation of CD25, CTLA-4 and CD40 ligand expression on CD4^+^ cells \[[@B14],[@B47]\], and increased tumor necrosis factor-α production by both CD4^+^ and CD8^+^ cells \[[@B47]\]. The TGF-β costimulated human CD4^+^ T cells are resistant to activation-induced apoptosis. They took up less annexin and expanded fivefold greater in primary cultures than control, alloactivated CD4^+^ T cells \[[@B14]\] (SG Zheng and DA Horwitz, unpublished observations, 2001). Some workers have reported that TGF-β can accelerate activation-induced cell death of some T cells \[[@B48],[@B49]\], while others observed that this cytokine protected T cells from apoptosis \[[@B50],[@B51]\]. We favor the hypothesis that TGF-β promotes the death of mature Th1 and Th2 cells while protecting newly generated regulatory T cells from undergoing apoptosis. This view is consistent with a report indicating positive effects of TGF-β on naive T cells \[[@B52]\].

In summary, using several different stimuli to activate T cells, we have found that the combination of IL-2 and TGF-β can induce CD4^+^and CD8^+^ T cells to become either cytokine-producing Th3-like or contact-dependent professional suppressor cells. In our studies with CD8^+^ cells, the cultures were always supplemented with IL-2. When human CD4^+^ cells are activated in the presence of TGF-β by irradiated allogeneic stimulator cells or with superantigens, however, sufficient IL-2 is produced for the costimulatory effects of TGF-β and suppressor cell differentiation. By contrast, cultures with mouse lymphocytes must generally be supplemented with IL-2.

As shown in Figure [2](#F2){ref-type="fig"}, we propose that TGF-β induces thymic-derived CD25 precursors in the naive fraction of CD4^+^ cells to expand and to become contact-dependent \'professional\' regulatory T cells. TGF-β also induces CD4^+^ and CD8^+^ cells that are CD25^-^ to become Th3-like cells. Although almost all naive CD4^+^ cells are CD25^-^, why the predominant TGF-β effect on T cells in this fraction is the generation of \'professional\' regulatory T cells remains to be determined. Our finding that both IL-2 and TGF-β are critical in the generation of regulatory T cells is of particular importance in patients with SLE since production of IL-2 and the active form of TGF-β is decreased \[[@B53]\].

*In vivo* effects of Treg
-------------------------

Cloned Th3 cells protect mice from several autoimmune diseases that include experimental allergic encephalitis, diabetes mellitus, colitis, and uveitis \[[@B20],[@B29],[@B54]-[@B56]\]. Cytokine-producing CD8^+^ cells were described initially \[[@B55]\], but reports of CD4^+^ cells with this characteristic have become predominant. Cloned Tr1 cells protect rodents from an experimental colitis \[[@B29]\]. Small numbers of adoptively transferred noncloned CD4^+^ CD25^+^ cells protect lymphopenic mice from developing spontaneous organ-specific autoimmune diseases and also protect animals from developing graft-versus-host disease \[[@B8]-[@B10],[@B57]\].

We have begun to learn whether regulatory T cells generated *ex vivo* with TGF-β can have protective effects *in vivo*. For this purpose, we selected a mouse model of SLE that has a rapid onset. The transfer of parental T cells to F1 mice can result in acute or chronic graft-versus-host disease depending on the precursor frequency of CD8^+^ parental cells reactive against the allogeneic MHC antigens \[[@B58],[@B59]\]. The transfer of DBA/2 T cells into DBA/2 × C57BL/6 F1 mice results in a lupus-like syndrome with high titers of anti-DNA antibodies and an immune complex glomerulonephritis. While alloactivated DBA/2 T cells accelerated the disease, alloactivation of splenic T cells or CD4^+^ cells in the presence of TGF-β markedly suppressed and even prevented the development of the lupus-like syndrome. Both anti-DNA antibody production and proteinuria were significantly suppressed \[[@B60]\]. Recent studies have revealed that these suppressor T cells can also alter the course of established disease. A single transfer of 5 million T cells conditioned with TGF-β markedly improved survival of these mice (SG Zheng and DA Horwitz, unpublished observations, 2001).

Since it has been possible to significantly expand regulatory T cells generated with TGF-β, it should be possible to generate sufficient numbers in humans for clinical trials. Although this will be carried out initially with mitogens as the T-cell activating agent, the ultimate goal is to induce autoantigen-specific regulatory T cells. This should be possible based on the progress being made in characterizing the pathogenic peptides that trigger autoimmune diseases. It may even be possible to induce potentially aggressive naive self-reactive cells to become protective suppressor cells by activating them with TGF-β. An adoptive immunotherapy using the patients own T cells that have regained a protective function they had lost should lack the serious toxic effects associated with the agents now in use. This treatment is especially promising in autoimmune diseases characterized by a relapsing and remitting course such as SLE, inflammatory bowel disease or certain forms of multiple sclerosis. The adoptive transfer of regulatory T cells generated *ex vivo* also has the potential to prevent the rejection of allogeneic organ transplants.

Abbreviations
=============

CTLA-4 = cytotoxic T-lymphocyte-associated antigen-4; TGF-β = transforming growth factor-β ; IL = interleukin; MHC = major histocompatibility complex; SLE = systemic lupus erythematosus; TCR = T-cell receptor; Th = T helper cells; Tr1 = Treg 1 regulatory CD4^+^ cells.
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![The role of transforming growth factor-β (TGF-β) in the differentiation pathway of CD8^+^ regulatory T cells. In response to antigen stimulation, the combination of IL-2 produced by CD4^+^ cells and the active form of TGF-β produced by natural killer (NK) cells or macrophages (not shown) induce CD8^+^ cells to lose their cytotoxic potential and become regulatory, TGF-β-producing, Th3-like cells. IL-2 also enhances the extracellular conversion of TGF-β from the latent to the biologically active form.](ar414-1){#F1}

![The role of transforming growth factor-β (TGF-β) in the differentiation pathway of CD4^+^ regulatory T cells. Following T-cell activation where a sufficient amount of IL-2 is produced to overcome the inhibitory effects of TGF-β, the costimulatory effects of this cytokine induce the precursors of CD4^+^ CD25^+^ T cells to become contact-dependent \'professional\' suppressor cells or induces CD4^+^ CD25^-^ cells to produce immunosuppressive quantities of TGF-β . IFN, interferon; Tr-1, Treg 1 regulatory CD4^+^ cells.](ar414-2){#F2}
